Adjuvant chemotherapy of non-small-cell lung cancer

por Douillard, J.Y.
Publicado 2013

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

por Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T
Publicado 2014

PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer recei...

por Rivera, F., Karthaus, M., Valladares-Ayerbes, M., Gallego, J., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado en Ann Oncol (2016)

PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective ana...

por Köhne, C.-H., Rivera, F., Taieb, J., Siena, S., Peeters, M., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado en Ann Oncol (2016)

PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with s...

por Peeters, M., Siena, S., Douillard, J.-Y., Rivera, F., Taieb, J., Koukakis, R., Demonty, G., Köhne, C.-H.
Publicado en Ann Oncol (2016)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

por Bennett, L, Zhao, Z, Barber, B, Zhou, X, Peeters, M, Zhang, J, Xu, F, Wiezorek, J, Douillard, J-Y
Publicado 2011

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

por Douillard, J Y, Lerouge, D, Monnier, A, Bennouna, J, Haller, A M, Sun, X S, Assouline, D, Grau, B, Rivière, A
Publicado 2001

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

por Cunningham, D, Wong, R P W, D'Haens, G, Douillard, J-Y, Robertson, J, Stone, A M, Van Cutsem, E
Publicado 2013

P-149 Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective po...

por Sobrero, A., Douillard, J.-Y., Rivera, F., Forget, F., Karthaus, M., Valladares-Ayerbes, M., Demonty, G., Guan, X., Peeters, M.
Publicado en Ann Oncol (2016)

Randomized Phase 3 Study of Panitumumab With FOLFOX4 Compared to FOLFOX4 Alone as 1(st)-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC): The PRIME Trial

por Douillard, J.Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M.E., Humblet, Y., Cunningham, D., Wolf, M., Gansert, J.
Publicado 2010

PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma

por Siena, S., Tabernero, J., Bodoky, G., Cunningham, D., Rivera, F., Ruff, P., Canon, J.-L., Koukakis, R., Demonty, G., Douillard, J.-Y.
Publicado en Ann Oncol (2016)

Selective modification of NMR relaxation time in human colorectal carcinoma by using gadolinium-diethylenetriaminepentaacetic acid conjugated with monoclonal antibody 19-9.

por Curtet, C, Tellier, C, Bohy, J, Conti, M L, Saccavini, J C, Thedrez, P, Douillard, J Y, Chatal, J F, Koprowski, H
Publicado 1986

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

por Conroy, T, Hebbar, M, Bennouna, J, Ducreux, M, Ychou, M, Llédo, G, Adenis, A, Faroux, R, Rebischung, C, Kockler, L, Douillard, J Y
Publicado 2010

Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies

por Boeckx, N., Koukakis, R., Op de Beeck, K., Rolfo, C., Van Camp, G., Siena, S., Tabernero, J., Douillard, J.-Y., André, T., Peeters, M.
Publicado en Ann Oncol (2017)

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

por Pujol, J. L., Monnier, A., Berille, J., Cerrina, M. L., Douillard, J. Y., Rivière, A., Grandgirard, A., Gouva, S., Bizzari, J. P., Le Chevalier, T.
Publicado 1994

Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

por Bennouna, J, Breton, J-L, Tourani, J-M, Ottensmeier, C, O'Brien, M, Kosmidis, P, Huat, T E, Pinel, M-C, Colin, C, Douillard, J-Y
Publicado 2006

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

por Sobrero, A, Grothey, A, Iveson, T, Labianca, R, Yoshino, T, Taieb, J, Maughan, T, Buyse, M, André, T, Meyerhardt, J, Shields, A F, Souglakos, I, Douillard, J -Y, Cervantes, A
Publicado en Ann Oncol (2018)

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

por Delord, J-P, Bennouna, J, Artru, P, Perrier, H, Husseini, F, Desseigne, F, François, E, Faroux, R, Smith, D, Piedbois, P, Naman, H, Douillard, J Y, Bugat, R
Publicado 2007

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

por Bennouna, J, Perrier, H, Paillot, B, Priou, F, Jacob, J H, Hebbar, M, Bordenave, S, Seitz, J F, Cvitkovic, F, Dorval, E, Malek, K, Tonelli, D, Douillard, J Y
Publicado 2006

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six ran...

por Arnold, D., Lueza, B., Douillard, J.-Y., Peeters, M., Lenz, H.-J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J.-P., Tabernero, J., Cervantes, A., Ciardiello, F.
Publicado en Ann Oncol (2017)